8-K: Semnur Pharmaceuticals and Denali Capital Acquisition Corp. Announce Letter of Intent for Business Combination

Semnur Pharmaceuticals and Denali Capital Acquisition Corp. have signed a letter of intent for a business combination, valuing Semnur at up to $2.0 billion.

Summary

• Semnur Pharmaceuticals, a subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. have signed a letter of intent for a proposed business combination.
• The deal values Semnur at up to $2.0 billion, subject to a third-party fairness opinion.
• The combined company is expected to have up to $40 million in cash on hand at closing, depending on SPAC share redemptions.
• The merger aims to create a publicly traded biopharma company focused on non-opioid pain management.
• The proceeds from the transaction will primarily fund the development of Semnur's lead product, SP-102 (SEMDEXA), a non-opioid treatment for sciatica.
• Scilex is expected to be the majority shareholder of the combined entity.
• Semnur's SP-102 has completed a Phase 3 trial, showing significant pain reduction and improvement in disability scores for sciatica patients.
• Market research projects peak annual sales for SP-102 to reach up to $3.6 billion within 5 years of launch.
• The U.S. has over 30 million people with low back and radicular pain, with a significant portion experiencing moderate to severe pain.
• The overall estimated number of epidural steroid injection (ESI) procedures in the U.S. is approximately 12.1 million, with lumbar radiculopathy/sciatica procedures comprising approximately 88% of all ESIs administered.

Sentiment

Score: 8

Explanation: The document is positive due to the potential merger, strong market opportunity, and positive Phase 3 trial results for SP-102. However, there are risks associated with the transaction and regulatory approvals.

Positives

• The proposed business combination provides significant funding for the development of SP-102.
• SP-102 has demonstrated positive Phase 3 trial results, showing significant pain reduction and improvement in disability scores.
• SP-102 has a large potential market, with peak sales projected to reach up to $3.6 billion annually.
• The combined company will be focused on non-opioid pain management, addressing a significant unmet medical need.
• Semnur has a strong management team with experience in neurology and pain management.
• SP-102 has been granted Fast Track status by the FDA.

Negatives

• The business combination is subject to a definitive merger agreement, board approvals, and shareholder approval, with no guarantee of completion.
• The pre-transaction equity value of Semnur is subject to adjustment based on a third-party fairness opinion.
• The expected cash on hand at closing is dependent on the number of SPAC shares redeemed, which could be lower than $40 million.
• The letter of intent is subject to change, including the consideration to be issued.

Risks

• There is no assurance that a definitive merger agreement will be entered into or that the proposed transaction will be completed.
• The transaction is subject to various approvals and conditions, including shareholder approval.
• The final terms of the merger agreement, including the valuation and consideration, are subject to change.
• The combined company's ability to achieve the expected benefits of the transaction is not guaranteed.
• The success of SP-102 is subject to regulatory approvals and market acceptance.
• The company faces risks related to clinical development, regulatory approvals, and commercialization of its products.
• There are risks associated with the unpredictability of trading markets and whether a market will be established for Scilex's common stock.

Future Outlook

The combined company expects to capitalize on Semnur's product candidate, SP-102, and anticipates seeking approval from the SPAC's shareholders in the second half of 2024, assuming the execution of a merger agreement.

Management Comments

• Jaisim Shah, CEO of Scilex, stated that this is an important milestone in unlocking the value of SP-102 and thanked the team for their work.
• Lei Huang, CEO of Denali Capital Acquisition Corp., expressed excitement about the potential of SP-102 and the opportunity to work with the Semnur team.

Industry Context

This announcement reflects a growing trend in the biopharmaceutical industry towards non-opioid pain management solutions, addressing the need for alternatives to traditional opioid-based treatments. The merger also highlights the use of SPACs as a route to public markets for promising biotech companies.

Comparison to Industry Standards

• The projected peak sales of $3.6 billion for SP-102 are significant, potentially placing it among the top-selling pain management drugs if achieved.
• The focus on a non-opioid treatment for sciatica aligns with the industry's shift away from opioid-based therapies, similar to companies developing alternatives for chronic pain.
• The use of a SPAC for a merger is a common strategy for biotech companies seeking to go public, similar to other recent biotech SPAC mergers.
• The 12.1 million epidural steroid injection procedures annually in the US highlights the large market opportunity for SP-102, comparable to other companies targeting similar patient populations.

Stakeholder Impact

• Shareholders of Scilex are expected to become majority holders of the combined company.
• Shareholders of Denali will vote on the proposed business combination.
• Patients with sciatica may benefit from a new non-opioid treatment option.
• Employees of Semnur and Scilex may experience changes due to the merger.
• The combined company will have access to capital for further development and commercialization.

Next Steps

• Negotiation of a definitive merger agreement.
• Approval by the SPAC's and Scilex's boards of directors.
• Satisfaction of conditions in the merger agreement.
• Approval of the transaction by the SPAC's shareholders.
• Filing of a registration statement on Form S-4 with the SEC.
• Seeking approval from the SPAC's shareholders in the second half of 2024.

Key Dates

Keywords

Semnur Pharmaceuticals, Denali Capital Acquisition Corp, SPAC, Business Combination, Merger, SP-102, SEMDEXA, Sciatica, Non-opioid, Pain Management, FDA Fast Track, Epidural Injection, Scilex Holding Company